First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    AbbVie Inc. (ABBV): the developments shaping its investment case

    Follow the evidence affecting AbbVie Inc.'s demand outlook, margins. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research AbbVie Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-15 · 5 reports
    AbbVie Gains 1.8% Following Citadel 500% Stake Increase in Defensive Rotation
    Channel: Increased institutional investor interest (Citadel's significant stake increase) and market sentiment favoring defensive, dividend-paying stocks. Positive short-term price momentum.
    Bullish· 1-3m
    2026-09-15 · 3 reports
    Citadel increases AbbVie stake over 500% amid institutional yield rotation
    Channel: Direct institutional demand, increased investor confidence, potential for further price appreciation due to yield-seeking flows.
    Bullish· 1-3m
    2026-09-06 · 6 reports
    Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGR
    Channel: Increased market size and demand for Rinvoq (upadacitinib), an oral JAK inhibitor for atopic dermatitis, directly boosting sales.
    Bullish· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-06-30revenueBullishPatient 're-switching' behavior from biosimilars back to Humira suggests more durable revenue stream post-patent cliff.
    2026-06-30revenueBullishPatient 're-switching' behavior from biosimilars back to Humira suggests more durable revenue than market expectations.
    2026-06-30revenueBullishPatient 're-switching' behavior from biosimilars back to Humira suggests more durable revenue streams than market expectations.
    2026-06-30revenueBullish16% of patients return to Humira after switching to biosimilars, suggesting slower revenue erosion than expected.
    2026-06-30revenueBullishPatient 're-switching' behavior back to Humira from biosimilars suggests a more durable revenue stream than previously modeled.
    2026-06-30revenueBullish16% of patients return to Humira after switching to biosimilars, suggesting slower revenue erosion than market expectations.
    2026-06-30revenueBullishPatient 're-switching' behavior from biosimilars back to Humira suggests slower revenue erosion than market expectations.
    2026-06-29revenueBullishPatient 're-switching' behavior from biosimilars back to Humira suggests slower revenue erosion than expected.
    2026-06-29revenueBullish16% of patients return to Humira after biosimilar switch, suggesting slower revenue erosion than expected.
    2026-06-29revenueBullishPatient 're-switching' behavior from biosimilars back to Humira suggests more durable revenue stream than market feared.
    2026-06-24marginBearishAcquisition of Apogee is expected to create near-term earnings dilution due to R&D costs.
    2026-06-24marginBearishAcquisition expected to create near-term earnings dilution due to R&D costs.
    2026-06-23marginBearishAcquisition is expected to create near-term earnings dilution due to R&D costs.
    2026-06-23share_countBullishAcquisition expected to create near-term earnings dilution due to R&D costs.
    2026-06-23marginBearishThe $10.9 billion acquisition of Apogee is expected to create near-term earnings dilution.
    2026-06-22share_countBullishThe acquisition of Apogee is expected to be accretive to adjusted diluted EPS beginning in 2032, implying long-term earnings growth despite initial cash outlay.
    2026-06-22share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-06-22net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-06-22revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    40 events mapped to ABBV since 2026-08-30. Evidence through 2026-09-25.

    DateEventChannelDirectionHorizonImpact
    2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReasonSecond-order effect: Potential for increased R&D efficiency and pipeline acceleration across the pharmaceutical industry, pressuring competitors to adopt similar technologies.watch3-12m0.20
    2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS SurgePeer comparison and investor sentiment regarding patent cliff management.mixed1-3m0.60
    2026-09-21Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surgePeer comparison within the pharmaceutical sector. BMY's success in diversifying away from patent-exposed drugs could set a positive precedent or highlight challenges for peers with similar patent cliff issues, like ABBV with Humira.mixed1-3m0.50
    2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2Peer performance in managing patent cliffs and transitioning to new growth drivers provides a comparative benchmark and potential read-across for investor sentiment.mixed3-12m0.60
    2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surgePeer comparison and investor sentiment spillover within the pharmaceutical sector, particularly for companies facing similar patent cliff challenges.mixed1-3m0.40
    2026-09-15AbbVie Gains 1.8% Following Citadel 500% Stake Increase in Defensive RotationIncreased institutional investor interest (Citadel's significant stake increase) and market sentiment favoring defensive, dividend-paying stocks. Positive short-term price momentum.Bullish1-3m0.70
    2026-09-15Citadel increases AbbVie stake over 500% amid institutional yield rotationDirect institutional demand, increased investor confidence, potential for further price appreciation due to yield-seeking flows.Bullish1-3m0.80
    2026-09-15Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend DemandIncreased institutional ownership, strong fundamental performance, defensive asset appeal.Bullish1-3m0.80
    2026-09-15Citadel Expands AbbVie Stake by Over 500% in Defensive RotationIncreased institutional ownership and potential 'flight to quality' in defensive sectors. Positive sentiment from a major hedge fund's conviction.Bullish1-3m0.70
    2026-09-15Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand RisesIncreased institutional ownership and demand for defensive, dividend-paying stocks. Citadel's significant increase in holdings signals strong conviction, potentially attracting other institutional investors.Bullish1-3m0.70
    2026-09-15Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive RotationDirect institutional capital inflow and increased investor demand for defensive assets. This reflects a positive re-rating of its stable cash flows and dividend yield in a high-interest-rate environment.Bullish1-3m0.80
    2026-09-15Citadel increases AbbVie position by over 500% amid defensive yield rotationIncreased institutional ownership, potential for continued defensive rotation, validation of investment thesis by a major fund.Bullish1-3m0.70
    2026-09-15Citadel Expands AbbVie Stake by Over 500% in Q2 2026Increased institutional demand and validation of investment thesis; potential for short squeeze if short interest is high.Bullish1-3m0.70
    2026-09-15Citadel expands AbbVie stake over 500% in Q2 defensive positioning moveIncreased institutional ownership, signaling confidence in defensive characteristics and potentially attracting further capital inflows. Reduced short-term selling pressure.Bullish1-3m0.70
    2026-09-15Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws CapitalIncreased institutional ownership and positive sentiment from a major hedge fund, potentially attracting further capital and supporting share price. The 'defensive dividend yield' aspect highlights its appeal in uncertain markets.Bullish1-3m0.70
    2026-09-15Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive RotationDirect institutional demand, validation of defensive investment thesis, potential for continued capital inflows.Bullish1-3m0.70
    2026-09-13Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoYIncreased competitive pressure in the immunology market, potentially impacting market share and pricing power for existing products.mixed3-12m0.60
    2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesCompetitive dynamics in the immunology market. LLY's strong performance, particularly with new launches, could intensify competition for ABBV's immunology portfolio, including Skyrizi and Rinvoq, and biosimilar erosion of Humira.mixed3-12m0.60
    2026-09-13Eli Lilly Expands Non-Incretin Growth as Immunology Revenue Hits $2.6B in H1Increased competitive pressure in the immunology market. LLY's success could imply market share shifts or intensified R&D spending across the sector.mixed3-12m0.40
    2026-09-13Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026AbbVie is a dominant player in immunology. LLY's growth, especially with new pipeline assets, could pose a long-term threat to ABBV's market leadership and future revenue streams.mixed3-12m0.50
    2026-09-12Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New LabelsIncreased competitive pressure in the immunology market, potentially impacting market share and pricing power.mixed3-12m0.40
    2026-09-12Eli Lilly H1 Immunology Revenue Hits $2.6B via Taltz and M&A PipelineIncreased competition in the immunology market from strong players like Eli Lilly could put pressure on market share and pricing for AbbVie's immunology portfolio, despite its established position.mixed3-12m0.50
    2026-09-12Eli Lilly Immunology Division Generates $2.6B in H1 2026 RevenueCompetitive landscape in immunology; market share dynamics.mixed3-12m0.60
    2026-09-12Eli Lilly Immunology Revenue Reaches $2.6B in H1, Growing 9% Year-Over-YearHeightened competition in the immunology therapeutic area, particularly with Eli Lilly's new product launches, could challenge AbbVie's market leadership and growth prospects for drugs like Humira (post-biosimilar) and Skyrizi/Rinvoq.mixed3-12m0.40
    2026-09-12Eli Lilly immunology sales reach $2.6B in H1 2026, rising 9% YoYIncreased competitive pressure in the immunology market. While AbbVie has a strong established presence with Humira and Skyrizi/Rinvoq, Lilly's growth indicates a formidable competitor gaining market share, potentially impacting AbbVie's future growth rates or pricing power in certain indications.mixed3-12m0.40
    2026-09-12Eli Lilly immunology revenue reaches $2.6B in H1 2026 on Taltz and M&A assetsIncreased competition in the immunology market from a strong Eli Lilly segment could put pressure on AbbVie's market share and pricing power, particularly as Humira biosimilar erosion continues.mixed3-12m0.60
    2026-09-12Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 to Diversify Beyond GLP-1Competitive landscape in immunology. LLY's growth could signal market expansion but also increased rivalry for market share.mixed3-12m0.40
    2026-09-12Eli Lilly Immunology Division Reaches $2.6B H1 Sales on 9 Percent GrowthIncreased competitive pressure in the immunology market, particularly from a growing LLY, offset by ABBV's established market leadership.mixed3-12m0.60
    2026-09-12Eli Lilly immunology division generates $2.6B in H1 revenue (+9% YoY) via M&A pushIncreased competitive pressure in the immunology market, potentially impacting market share and pricing power.mixed3-12m0.40
    2026-09-12Eli Lilly posts $2.6B in H1 immunology revenue, up 9% YoYHeightened competition in the immunology space, particularly as AbbVie navigates biosimilar erosion for Humira and relies on Skyrizi and Rinvoq for growth. Strong LLY performance could challenge ABBV's growth trajectory.mixed3-12m0.40
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 at 7.7% CAGRIncreased market size and demand for Rinvoq (upadacitinib), an oral JAK inhibitor for atopic dermatitis, directly boosting sales.Bullish3-12m0.70
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.42B by 2035 on Biologics DemandIncreased adoption and market expansion for Rinvoq (upadacitinib), a JAK inhibitor for atopic dermatitis, contributing to pharmaceutical sales growth.Bullish1-5y0.70
    2026-09-06Atopic dermatitis therapeutic market projected to reach $33.42B by 2035 on biologicsIncreased market opportunity for Rinvoq, a JAK inhibitor approved for atopic dermatitis. Growth in the overall market could offset competitive pressures or expand the patient pool for JAK inhibitors.Bullish3-12m0.75
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics ExpansionIncreased market size and demand for Rinvoq (JAK inhibitor) in atopic dermatitis.Bullish1-5y0.70
    2026-09-06Atopic Dermatitis Biopharma Market Projected to Reach $33.4B by 2035 at 7.7% CAGRIncreased market size and demand for Rinvoq (upadacitinib), a JAK inhibitor approved for atopic dermatitis, bolstering immunology segment sales.Bullish3-12m0.70
    2026-09-06Atopic Dermatitis Market Projected to Reach $33.4B by 2035 on Biologics GrowthIncreased market size and adoption for Rinvoq, a JAK inhibitor approved for atopic dermatitis.Bullish1-5y0.70
    2026-09-03Aptevo Therapeutics Reports 93% Clinical Benefit Rate with Mipletamig Triplet in AMLPotential competitive pressure in the AML treatment landscape, particularly for TP53-mutated patients, if mipletamig progresses.watch3-12m0.10
    2026-09-03AbbVie Inc. Acquires Apogee Therapeutics, Inc. ($11B)Direct acquisition impact on financial statements and strategic positioning. Integration risks and potential for pipeline success.mixed3-12m0.70
    2026-08-30Eli Lilly GLP-1 Revenue Hits Nearly Two-Thirds of Sales Amid 45% Top-Line GrowthBroader pharmaceutical sector trends; while not directly in the GLP-1 race, investor focus on high-growth areas like GLP-1s could shift capital away from other therapeutic areas.watch1-5y0.20
    2026-08-30Eli Lilly Posts 45% Top-Line Growth but Faces Two-Thirds GLP-1 Revenue ConcentrationIndirect competitive pressure and investor rotation towards growth leaders.Bearish3-12m0.60

    Continue this research

    Build your AbbVie Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the ABBV entity page →

    Research AbbVie Inc. · $399/mo